Anne Sophie Czerniak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anne Sophie Czerniak has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Annette Gabriele Beck‐Sickinger
Institute of Biochemistry Leipzig University Leipzig Germany
2 shared publications - Kevin Kretschmer
Institute of Biochemistry Faculty of Life Sciences Leipzig University Brüderstr. 34 04103 Leipzig Germany
1 shared publication - Lina Zielke
Rudolf Schönheimer Institute of Biochemistry, Division of General Biochemistry, Medical Faculty, Leipzig University, Leipzig, Germany
1 shared publication - Sylvia Els-Heindl
Universität Leipzig
1 shared publication Tina Weiß
Institute of Biochemistry Faculty of Life Sciences Leipzig University Brüderstr. 34 04103 Leipzig Germany
1 shared publication- Tina Weiß
Institute of Biochemistry, Leipzig University, Brüderstraße 34, 04103 Leipzig, Germany
1 shared publication
Latest Publications
- Open Access
- 26 October 2022
- Published by Wiley in ChemMedChem
- Vol. 17 (23)
The Chemerin Receptor CMKLR1 Requires Full‐Length Chemerin for High Affinity in Contrast to GPR1 as Demonstrated by a New Nanoluciferase‐Based Binding Assay
To study the binding mode of the adipokine chemerin as well as the short peptide agonist chemerin‐9 (C9) to its two receptors chemokine‐like receptor 1 (CMKLR1) and G protein‐coupled receptor 1 (GPR1), we generated 5‐carboxytetramethylrhodamine (TAMRA) modified variants of both ligands. In addition, we labeled GPR1 and CMKLR1 with a nanoluciferase at the N‐terminus to perform NanoBRET binding assays. For GPR1, both ligands show high affinity and comparable binding. Significant differences were found for CMKLR1, whereby only full‐length chemerin binds with high affinity in saturation and displacement assays. For TAMRA‐C9 a biphasic binding consisting of two binding states has been found and no displacement studies could be performed. Thus, we conclude that CMKLR1 requires full‐length chemerin for stable binding in contrast to GPR1. This work demonstrates the NanoBRET binding assay as a new tool for binding studies at chemerin receptors and it enables deeper insights into the ligand binding parameters.
- 26 October 2022
- Published by Wiley in ChemMedChem
- Vol. 17 (23)
Open AccessThe Chemerin Receptor CMKLR1 Requires Full‐Length Chemerin for High Affinity in Contrast to GPR1 as Demonstrated by a New Nanoluciferase‐Based Binding Assay
To study the binding mode of the adipokine chemerin as well as the short peptide agonist chemerin‐9 (C9) to its two receptors chemokine‐like receptor 1 (CMKLR1) and G protein‐coupled receptor 1 (GPR1), we generated 5‐carboxytetramethylrhodamine (TAMRA) modified variants of both ligands. In addition, we labeled GPR1 and CMKLR1 with a nanoluciferase at the N‐terminus to perform NanoBRET binding assays. For GPR1, both ligands show high affinity and comparable binding. Significant differences were found for CMKLR1, whereby only full‐length chemerin binds with high affinity in saturation and displacement assays. For TAMRA‐C9 a biphasic binding consisting of two binding states has been found and no displacement studies could be performed. Thus, we conclude that CMKLR1 requires full‐length chemerin for stable binding in contrast to GPR1. This work demonstrates the NanoBRET binding assay as a new tool for binding studies at chemerin receptors and it enables deeper insights into the ligand binding parameters.
- Open Access
Cyclic Derivatives of the Chemerin C-Terminus as Metabolically Stable Agonists at the Chemokine-like Receptor 1 for Cancer Treatment
Chemerin is a small chemotactic protein and a modulator of the innate immune system. Its activity is mainly mediated by the chemokine-like receptor 1 (CMKLR1), a receptor expressed by natural killer cells, dendritic cells, and macrophages. Downregulation of chemerin is part of the immune evasion strategy exploited by several cancer types, including melanoma, breast cancer, and hepatocellular carcinoma. Administration of chemerin can potentially counteract these effects, but synthetically accessible, metabolically stable analogs are required. Other tumors display overexpression of CMKLR1, offering a potential entry point for targeted delivery of chemotherapeutics. Here, we present cyclic derivatives of the chemerin C-terminus (chemerin-9), the minimal activation sequence of chemerin. Chemerin-9 derivatives that were cyclized through positions four and nine retained activity while displaying full stability in blood plasma for more than 24 h. Therefore, these peptides could be used as a drug shuttle system to target cancer cells as demonstrated here by methotrexate conjugates.
Open AccessCyclic Derivatives of the Chemerin C-Terminus as Metabolically Stable Agonists at the Chemokine-like Receptor 1 for Cancer Treatment
Chemerin is a small chemotactic protein and a modulator of the innate immune system. Its activity is mainly mediated by the chemokine-like receptor 1 (CMKLR1), a receptor expressed by natural killer cells, dendritic cells, and macrophages. Downregulation of chemerin is part of the immune evasion strategy exploited by several cancer types, including melanoma, breast cancer, and hepatocellular carcinoma. Administration of chemerin can potentially counteract these effects, but synthetically accessible, metabolically stable analogs are required. Other tumors display overexpression of CMKLR1, offering a potential entry point for targeted delivery of chemotherapeutics. Here, we present cyclic derivatives of the chemerin C-terminus (chemerin-9), the minimal activation sequence of chemerin. Chemerin-9 derivatives that were cyclized through positions four and nine retained activity while displaying full stability in blood plasma for more than 24 h. Therefore, these peptides could be used as a drug shuttle system to target cancer cells as demonstrated here by methotrexate conjugates.